Introduction
Carcinoma of the adrenal cortex is rare, affecting about 1/500 000 persons (Hutter and Kayhoe, 1966) . Untreated, the disease is rapidly fatal with a mean survival of 3 months (Macfarlane, 1958) . Although 25% of patients can be 'cured' of their Cushing's syndrome by surgical removal of the primary adrenal tumour (Liddle, 1974) , treatment is generally unsatisfactory, with a high early recurrence rate after surgery and a poor response to medical therapy.
Long-term survival with relapse is unusual and only the very rare late recurrence up to 16 years after initial presentation has been recorded (Harrison and Abelson, 1952 (Crowley, 1976) . In a review of 138 patients with adrenal cortical carcinoma, Hutter and Kayhoe (1966) found evidence of local spread of tumour in 65% patients on first presentation, of metastatic spread to lungs in 53 %, to liver in 44% and to distant lymph nodes in 11 %.
Untreated, the prognosis is poor. Hutter and Kayhoe treated patients with the adrenolytic agent, o,p'-DDD, and of these, only 52% females and 38% males were alive at 4 years, with a mean survival of 56 and 19 months respectively. Further experience with o,p'-DDD has confirmed its limited value in treatment (Orth and Liddle, 1971 Steroid secretion by the tumour secondaries could have resulted in complete atrophy of the remaining adrenal gland. This might have established a vicious cycle, once the metastases were removed, allowing plasma corticotrophin levels to rise and thus stimulating further tumour recurrence.
Subsequent treatment with replacement doses of hydrocortisone has suppressed pituitary release of corticotrophin, and the patient on combined hydrocortisone and oestrogen therapy has remained well. She has now survived for 27 years after the removal of the primary tumour, and 5 years after metastases in the lung first became apparent. 
